霍乱卫生经济学:系统综述
该系统综述检索截至2017年2月的文献,评估霍乱疾病负担与疫苗接种的经济学证据。多数情况下每例霍乱病例成本低于100美元,纳入更广泛社会经济成本则超过1000美元/例。疫苗针对高发病率人群或高病死率地区具有经济价值,考虑群体免疫时对一般人群也具成本效果。
要点
- 多数情况下每例霍乱病例成本低于100美元。
- 纳入更广泛社会经济成本时每例超过1000美元。
- 疫苗针对高发病率人群或高病死率地区具经济价值。
核心结论
- 霍乱疫苗接种是可行的短至中期选择,尤其对面临显著霍乱负担的国家而言,供水和环境卫生(WASH)基础设施前期成本更高。
- 长期而言,WASH若实施得当可能是更具成本效果的解决方案,但霍乱疫苗接种仍是可行且具成本效果的策略。
研究设计与样本
- 系统综述,检索PubMed、Econlit、Embase、Web of Science和Cochrane Review,无日期限制,截至2017年2月。
- 去重后共筛选1993项研究,由两名评价者独立编码,最终纳入22项相关研究。
- 比较不同国家/地区的人群、方法及结果(疾病成本与疫苗接种成本效果),所有成本调整为2017年美元以便比较。
主要发现
- 多数情况下每例霍乱病例成本低于100美元,即使考虑患者/家庭承担的成本和生产力损失也是如此。
- 纳入更广泛的社会经济成本时,估计每例成本超过1000美元。
- 当疫苗接种针对高发病率人群和/或霍乱病死率高的地区时,有足够证据支持其预防和控制霍乱的经济价值。
- 考虑群体免疫时,疫苗接种对一般人群也具成本效果,且成本效果与其他常规免疫接种相当。
关键数值与推荐
- 每例霍乱病例成本:多数情况下低于100美元;纳入更广泛社会经济成本时超过1000美元/例。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Vibrio cholera is a major contributor of diarrheal illness that causes significant morbidity and mortality globally. While there is literature on the health economics of diarrheal illnesses more generally, few studies have quantified the cost-of-illness and cost-effectiveness of cholera-specific prevention and control interventions. The present systematic review provides a comprehensive overview of the literature specific to cholera as it pertains to key health economic measures. METHODS: A systematic review was performed with no date restrictions up through February 2017 in PubMed, Econlit, Embase, Web of Science, and Cochrane Review to identify relevant health economics of cholera literature. After removing duplicates, a total of 1993 studies were screened and coded independently by two reviewers, resulting in 22 relevant studies. Data on population, methods, and results (cost-of-illness and cost-effectiveness of vaccination) were compared by country/region. All costs were adjusted to 2017 USD for comparability. RESULTS: Costs per cholera case were found to be rather low: <$100 per case in most settings, even when costs incurred by patients/families and lost productivity are considered. When wider socioeconomic costs are included, estimated costs are >$1000/case. There is adequate evidence to support the economic value of vaccination for the prevention and control of cholera when vaccination is targeted at high-incidence populations and/or areas with high case fatality rates due to cholera. When herd immunity is considered, vaccination also becomes a cost-effective option for the general population and is comparable in cost-effectiveness to other routine immunizations. CONCLUSIONS: Cholera vaccination is a viable short-to-medium term option, especially as the upfront costs of building water, sanitation, and hygiene (WASH) infrastructure are considerably higher for countries that face a significant burden of cholera. While WASH may be the more cost-effective solution in the long-term when implemented properly, cholera vaccination can still be a feasible, cost-effective strategy.
引用
- Hsiao A, Hall AH, Mogasale V, et al. The health economics of cholera: A systematic review. Vaccine. 2018. PMID: 29907482. doi:10.1016/j.vaccine.2018.05.120
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。